The projected increase in collaboration revenue for Alector suggests positive growth and potential profitability, which could lead to increased investor confidence and a potential rise in stock price. However, the high R&D expenses indicate significant investment in research, which is common in the biotech industry and necessary for long-term growth. The net impact on the stock price is likely positive in the short term, as the market often reacts favorably to revenue growth projections.